|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Microsatellite alterations on several chromosomes and mutations in the p53 gene were frequent in differentiated adenocarcinomas, even those at an early stage.
|
7728762 |
1995 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Single-strand conformational polymorphism analysis and direct DNA sequencing were used to detect p53 gene mutations in 37 pancreatic adenocarcinomas. p53 gene mutations were detected in 16 (43%) of the 37 pancreatic adenocarcinomas.
|
7730141 |
1995 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence, Italy.
|
7780983 |
1995 |
|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Abnormalities of the tumour suppressor gene p53 have been shown in approximately 60% of advanced gastric adenocarcinomas and it has been suggested that the immunohistochemical finding of increased p53 expression is a prognostic marker in gastric cancer.
|
7829004 |
1994 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Gene alterations of p53 tumor suppressor gene such as point mutations, deletions or insertions occur in various human cancers. p53 protein overexpression was studied immunohistochemically in 80 gastric adenocarcinomas using an anti-human p53 antibody (Pab 1801) and the avidin-biotin-peroxidase technique.
|
7848577 |
1994 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Mutations in the p53 gene occurred more frequently in serous adenocarcinomas (14/31, 45%) than in all nonserous types of malignant epithelial tumors combined (7/34, 21%; P = 0.032).
|
7852189 |
1994 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Several investigators have found that p53 alteration is a frequent event in oesophageal adenocarcinomas and is associated with malignant transformation of Barrett's oesophagus. p53 appears to be a promising prognostic marker in Barrett's oesophagus and, as research progresses, possible clinical applications are emerging.
|
7866817 |
1995 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
We propose that inactivation of both p53 and Rb genes may promote cell divisions causing telomere shortening in lung cancer as in the two-stage model, while there may be another pathway to overcome both M1 and M2 mechanisms, especially for adenocarcinoma.
|
7898935 |
1995 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Increased nuclear accumulation of p53 protein was found in 11 adenocarcinomas (38%).
|
7905543 |
1994 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
In the samples positive for p53 protein, gene mutations in exons 5, 7 and 8 were detected by utilizing single-strand conformation polymorphism analysis (SSCP) in 1 Barrett's metaplasia specimen and 6 adenocarcinomas.
|
7906678 |
1994 |
|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
The results suggest that overexpression of p53 protein is of marginal prognostic value in local prostatic adenocarcinomas, whereas direct measurement of cell proliferation by PCNA immunolabelling provides important prognostic information in T1-2M0 tumours, in addition to the Gleason score.
|
7913085 |
1994 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Although the rate of p53 mutations in pancreatic tumours is of the same order as in other adenocarcinomas (> or = 50%), an antibody response was found in only 5/78 (6.4%) sera from patients with pancreatic cancer.
|
7947080 |
1994 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
CTD_mouse |
Overexpression of p53 protein, which is frequently demonstrated in virulent phenotypes of human corpus cancers, was seen in three out of eight (38%) adenocarcinomas, but not in the atypical hyperplasia or normal endometrial glands.
|
7955072 |
1994 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
The pattern of p53 mutations differed between isthmus and cervical adenocarcinomas: all of the mutations in the former were one-base substitutions of the transition type, whereas in the latter nearly half of the mutations were of the transversion type.
|
7960232 |
1994 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence.
|
8020801 |
1994 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
In 40 sporadic gastric adenocarcinomas, nine tumors (22.5%) with p53 mutations in exons 5-8, and six tumors (15%) with the USM+ phenotype, were detected.
|
8062274 |
1994 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Expression of the p53 protein was analyzed in 36 cases of carcinoma in adenoma in the colon by immunohistochemistry using an anti-human p53 monoclonal antibody (PAb1801).
|
8062281 |
1994 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
This study was conducted to investigate the p53 gene alterations in 25 surgically-resected gastric adenocarcinomas in the Korea Cancer Center Hospital by polymerase chain reaction single-strand conformation polymorphism analysis (PCR-SSCP) for exons 4-8 and immunohistochemical staining (IHCS) with anti-p53 antibody, DO-7. p53 mutations were detected in nine (36%) out of 25 cancer tissues by PCR-SSCP in exon 4-8: 0,1,1,6 and 1 mutations in exons 4,5,6,7 and 8, respectively.
|
8067692 |
1994 |
|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
To assess potential clinical applications for molecular genetic markers associated with human esophageal tumorigenesis, ten patients with primary esophageal adenocarcinomas were studied prospectively to evaluate expression of the p53 and H-ras genes.
|
8076380 |
1994 |
|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Cases of multiple synchronous adenomas showed different patterns of p53 expression but more positivity was found in adenomas from patients with a synchronous adenocarcinoma.
|
8076381 |
1994 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
APC and p53 mutations in de novo colorectal adenocarcinomas.
|
8081386 |
1994 |
|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
In this study we investigated immunohistochemically the expression of p53 and c-erbB-2 proteins in 30 gall bladder adenocarcinomas, one carcinoma in situ, eight gall bladder epithelial dysplasias, and four cases of chronic cholecystitis. p53 expression could be found in 14 (47 per cent) adenocarcinomas and in two out of eight epithelial dysplasias.
|
8100854 |
1993 |
|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Alterations of the retinoblastoma (Rb) gene were evaluated in nine primary endometrial adenocarcinomas that we had previously analyzed for the presence of Ki-ras activations and p53 alterations and in three endometrial carcinoma cell lines.
|
8105795 |
1993 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas.
|
8158699 |
1994 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Aneuploid cell populations from Barrett's adenocarcinomas have a high prevalence of 17p allelic losses, and there is substantial evidence that the target of these losses is the p53 gene.
|
8162566 |
1994 |